NCT02635243WITHDRAWNanonymous

SAR438544 - Clinical & Exploratory Pharmacology

Sponsor

Source record

Sanofi

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

SAR438544, r-glucagon, insulin

Indication / condition

AI-normalized

Type 1 Diabetes Mellitus

Intervention

Source record

SAR438544, r-glucagon, insulin

Related intelligence directories

Indication directory: Type 1 Diabetes Mellitus Modality directory: small molecule Target directory: SAR438544

Source & freshness

Source record

NCT ID

NCT02635243

Original source

ClinicalTrials.gov

Source last updated

Detailed source ingestion pending.

Ingested at

Jul 25, 2026

Internal sync

Jul 25, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT02635243

Title

SAR438544 - Clinical & Exploratory Pharmacology

Sponsor

Sanofi

Status

WITHDRAWN

Phase

PHASE1

Condition raw

Type 1 Diabetes Mellitus

Condition normalized

Type 1 Diabetes Mellitus

Modality raw

small molecule

Modality normalized

small molecule

Target raw

SAR438544, r-glucagon, insulin

Target normalized

SAR438544, r-glucagon, insulin

Interventions

SAR438544, r-glucagon, insulin

Public preview

Source record

SAR438544 - Clinical & Exploratory Pharmacology is a PHASE1 clinical asset sponsored by Sanofi in Type 1 Diabetes Mellitus. SEO and diligence focus: SAR438544, r-glucagon, insulin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

SAR438544 - Clinical & Exploratory Pharmacology

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jul 28, 2026

Report code

NCT02635243-Jul 28, 2026

NCT ID

NCT02635243

Status

WITHDRAWN

Phase

PHASE1

Sponsor

Sanofi

Executive brief

Investment-Ready Snapshot

SAR438544

Clinical & Exploratory Pharmacology is a PHASE1 clinical asset sponsored by Sanofi in Type 1 Diabetes Mellitus. SEO and diligence focus: SAR438544, r-glucagon, insulin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedDetailed source ingestion pending.

Internal syncJul 25, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02635243

Indication

Type 1 Diabetes Mellitus

Modality

small molecule

Target

SAR438544, r-glucagon, insulin

Intervention

SAR438544, r-glucagon, insulin

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.